<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92371">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01859754</url>
  </required_header>
  <id_info>
    <org_study_id>GAM5-28</org_study_id>
    <nct_id>NCT01859754</nct_id>
  </id_info>
  <brief_title>Octagam 5% Versus Comparator Post Marketing Trial</brief_title>
  <official_title>Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam速 Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Octapharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Octapharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Design:

      This is a 2 arm non-interventional trial that will compare the occurrence of adverse drug
      reactions between Octagam 5% and other marketed IVIG infusion treatments.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Post Marketing Study is a prospective, 2-armed, multicenter, non-interventional study.
      Patients will either be administered the brand of IGIV therapy ordered by their prescribing
      physician, or for patients issued unspecified or generic prescriptions of IGIV therapy,
      octagam速 5% or another brand of IGIV therapy will be provided by the Investigator according
      to federal, state and local regulations and good clinical practice (GCP) guidelines.

      The primary objective is to assess and evaluate the safety profile of octagam速 5% during or
      after administration under routine clinical use for all labeled indications, with a special
      emphasis on the occurrence of TEEs. The incidence of TEEs in patients receiving octagam速 5%
      will be compared with the incidence rate in a matching concurrent control group of patients
      receiving other IGIVs for routine clinical use.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">August 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Incidence Rate of Thromboembolytic events</measure>
    <time_frame>4 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Primary Immune Deficiency Disorder</condition>
  <arm_group>
    <arm_group_label>Octagam 5%</arm_group_label>
    <description>Primary Immune Deficiency Syndrome patients receiving Octagam 5% by infusion who have been treated with a marketed IVIG product for at least 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other marketed IVIG product</arm_group_label>
    <description>Primary Immune Deficiency Syndrome patients receiving marketed IVIG product other than Octagam 5% by infusion as treatment for at least 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Octagam 5%</intervention_name>
    <description>Intravenous immunoglobulin 5%</description>
    <arm_group_label>Octagam 5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Other marketed IVIG product</intervention_name>
    <description>Any intravenous immunoglobulin marketed product approved for the treatment of PID</description>
    <arm_group_label>Other marketed IVIG product</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients over 18 years old with Primary Immune Deficiency Syndrome PID receiving marketed
        IVIG as treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients aged 18 years.

          2. Patients with confirmed diagnosis of Primary Humoral Immunodeficiency (PI) as stated
             by the World Health Organization and requiring immunoglobulinreplacement therapy due
             to hypogammaglobulinemia or agammaglobulinemia.

          3. Patients on regular treatment (every 3 to 4 weeks) with low dose IGIV (1 g/kg) for a
             period of at least 6 months without changing the brand.

        Exclusion Criteria:

          1. Patients with a history of TEEs within the previous 24 months.

          2. Patients with a regular treatment frequency of more than once every 3 to 4 weeks.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Frenzel</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Medical Monitor, Octapharma AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergy and Asthma Relief Experts</name>
      <address>
        <city>Granada Hills</city>
        <state>California</state>
        <zip>91344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Araceli Vasquez, MD</last_name>
      <phone>818-366-8112</phone>
      <phone_ext>112</phone_ext>
      <email>araceli@asthmadoc.com</email>
    </contact>
    <investigator>
      <last_name>Jacob Offenberger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maritza Clawges</last_name>
      <phone>949-824-2032</phone>
      <email>mclawges@uci.edu</email>
    </contact>
    <investigator>
      <last_name>Sudhir Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Immunoe Research</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Ullate</last_name>
      <email>LUllate@immunoe.com</email>
    </contact>
    <investigator>
      <last_name>Isaac Melamed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asthma and Allergy Associates of Omaha</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ai Lan Kobayashi, MD</last_name>
      <email>midlandspeds@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Roger Kobayashi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Calcances, RN</last_name>
      <phone>631-751-3000</phone>
      <email>georgenicholas26@aol.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Vacirca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Optimed Research Ltd</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Urbank, NP</last_name>
      <phone>614-430-8022</phone>
      <phone_ext>109</phone_ext>
      <email>ann@optimed.us.com</email>
    </contact>
    <investigator>
      <last_name>Donald McNeil, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Toledo Institute of Clinical Research, Inc.</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43617</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Bak</last_name>
      <phone>419-843-8815</phone>
      <email>coral_expressions@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Syed Rehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital of Rhode Island</name>
      <address>
        <city>Pawtucket</city>
        <state>Rhode Island</state>
        <zip>02860</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patti Wingate</last_name>
      <phone>401-729-2225</phone>
      <email>patti_wingate@mhri.org</email>
    </contact>
    <investigator>
      <last_name>Iole Ribizzi-Akhtar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BreatheAmerica, Inc.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Gomillion</last_name>
      <phone>615-665-7130</phone>
      <email>jgomillion@breatheamerica.com</email>
    </contact>
    <investigator>
      <last_name>David Hagaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AARA Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Tucker</last_name>
      <phone>214-365-0365</phone>
      <email>jtucker@aararesearch.com</email>
    </contact>
    <investigator>
      <last_name>William Lumry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>May 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Immune Deficiency Syndrome</keyword>
  <keyword>Primary immunodeficiency Disease (PIDD)</keyword>
  <keyword>PID</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
